Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Lett ; 561: 216139, 2023 05 01.
Article in English | MEDLINE | ID: mdl-37001752

ABSTRACT

Despite the success of immune checkpoint blockade for cancer therapy, many patients do not respond adequately. We aimed to improve this therapy by optimizing both the antibodies and their delivery route, using small monodomain antibodies (nanobodies) delivered locally with a self-amplifying RNA (saRNA) vector based on Semliki Forest virus (SFV). We generated nanobodies against PD-1 and PD-L1 able to inhibit both human and mouse interactions. Incorporation of a dimerization domain reduced PD-1/PD-L1 IC50 by 8- and 40-fold for anti-PD-L1 and anti-PD-1 nanobodies, respectively. SFV viral particles expressing dimeric nanobodies showed a potent antitumor response in the MC38 model, resulting in >50% complete regressions, and showed better therapeutic efficacy compared to vectors expressing conventional antibodies. These effects were also observed in the B16 melanoma model. Although a short-term expression of nanobodies was observed due to the cytopathic nature of the saRNA vector, it was enough to generate a strong proinflammatory response in tumors, increasing infiltration of NK and CD8+ T cells. Delivery of the SFV vector expressing dimeric nanobodies by local plasmid electroporation, which could be more easily translated to the clinic, also showed a potent antitumor effect.


Subject(s)
Neoplasms , Single-Domain Antibodies , Animals , Humans , Mice , B7-H1 Antigen/genetics , CD8-Positive T-Lymphocytes , Semliki forest virus/genetics , Single-Domain Antibodies/genetics , Programmed Cell Death 1 Receptor/metabolism
2.
Mol Ther Oncolytics ; 26: 246-264, 2022 Sep 15.
Article in English | MEDLINE | ID: mdl-35949950

ABSTRACT

The outcomes of metastatic and nonresponder pediatric osteosarcoma patients are very poor and have not improved in the last 30 years. These tumors harbor a highly immunosuppressive environment, making existing immunotherapies ineffective. Here, we evaluated the use of Semliki Forest virus (SFV) vectors expressing galectin-3 (Gal3) inhibitors as therapeutic tools, since both the inhibition of Gal3, which is involved in immunosuppression and metastasis, and virotherapy based on SFV have been demonstrated to reduce tumor progression in different tumor models. In vitro, inhibitors based on the Gal3 amino-terminal domain alone (Gal3-N) or fused to a Gal3 peptide inhibitor (Gal3-N-C12) were able to block the binding of Gal3 to the surface of activated T cells. In vivo, SFV expressing Gal3-N-C12 induced strong antitumor responses in orthotopic K7M2 and MOS-J osteosarcoma tumors, leading to complete regressions in 47% and 30% of mice, respectively. Pulmonary metastases were also reduced in K7M2 tumor-bearing mice after treatment with SFV-Gal3-N-C12. Both the antitumor and antimetastatic responses were dependent on modulation of the immune system, primarily including an increase in tumor-infiltrating lymphocytes and a reduction in the immunosuppressive environment inside tumors. Our results demonstrated that SFV-Gal3-N-C12 could constitute a potential therapeutic agent for osteosarcoma patients expressing Gal3.

3.
JCI Insight ; 7(7)2022 04 08.
Article in English | MEDLINE | ID: mdl-35393952

ABSTRACT

Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors, and patient survival has not changed despite many therapeutic efforts, emphasizing the urgent need for effective treatments. Here, we evaluated the anti-DIPG effect of the oncolytic adenovirus Delta-24-ACT, which was engineered to express the costimulatory ligand 4-1BBL to potentiate the antitumor immune response of the virus. Delta-24-ACT induced the expression of functional 4-1BBL on the membranes of infected DIPG cells, which enhanced the costimulation of CD8+ T lymphocytes. In vivo, Delta-24-ACT treatment of murine DIPG orthotopic tumors significantly improved the survival of treated mice, leading to long-term survivors that developed immunological memory against these tumors. In addition, Delta-24-ACT was safe and caused no local or systemic toxicity. Mechanistic studies showed that Delta-24-ACT modulated the tumor-immune content, not only increasing the number, but also improving the functionality of immune cells. All of these data highlight the safety and potential therapeutic benefit of Delta-24-ACT the treatment of patients with DIPG.


Subject(s)
Brain Stem Neoplasms , Diffuse Intrinsic Pontine Glioma , Oncolytic Virotherapy , Adenoviridae , Animals , Brain Stem Neoplasms/genetics , Brain Stem Neoplasms/pathology , Brain Stem Neoplasms/therapy , Humans , Mice
4.
Curr Opin Virol ; 44: 145-153, 2020 10.
Article in English | MEDLINE | ID: mdl-32898764

ABSTRACT

DNA or mRNA vaccines have potential advantages over conventional vaccines since they are easier to manufacture and have higher safety profiles. In particular, self-amplifying RNA (saRNA) derived from alphavirus expression vectors has shown to be very efficient to induce humoral and cellular responses against many antigens in preclinical models, being superior to non-replicating mRNA and DNA. This is mainly due to the fact that saRNA can provide very high expression levels and simultaneously induces strong innate responses, potentiating immunity. saRNA can be administered as viral particles or DNA, but direct delivery as RNA represents a safer and more simple approach. Although saRNA can be delivered as naked RNA, in vivo transfection can be enhanced by electroporation or by complexing it with cationic lipids or polymers. Alphavirus saRNA could have broad application to vaccinate against human pathogens, including emerging ones like SARS-CoV-2, for which clinical trials have been recently initiated.


Subject(s)
Alphavirus/genetics , COVID-19 Vaccines/immunology , COVID-19/prevention & control , SARS-CoV-2/immunology , Vaccines, DNA/immunology , COVID-19/immunology , COVID-19 Vaccines/genetics , Humans , RNA, Messenger/genetics
5.
Ambio ; 49(2): 541-556, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31301003

ABSTRACT

Primary production hotspots in the marine environment occur where the combination of light, turbulence, temperature and nutrients makes the proliferation of phytoplankton possible. Satellite-derived surface chlorophyll-a distributions indicate that these conditions are frequently associated with sharp water mass transitions named "marine fronts". Given the link between primary production, consumers and ecosystem functions, marine fronts could play a key role in the production of ecosystem services (ES). Using the shelf break front in the Argentine Sea as a study case, we show that the high primary production found in the front is the main ecological feature that supports the production of tangible (fisheries) and intangible (recreation, regulation of atmospheric gases) marine ES and the reason why the provision of ES in the Argentine Sea concentrates there. This information provides support to satellite chlorophyll as a good indicator of multiple marine ES. We suggest that marine fronts could be considered as marine ES hot spots.


Subject(s)
Ecosystem , Fisheries , Phytoplankton , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...